Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Trial Profile

An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SUSTAIN-3
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 05 Sep 2023 According to a Janssen media release, sub-group analysis of this trial will be presented at the Psych Congress 2023.
    • 09 Aug 2023 Interim results of subgroup analysis (n=32) assessing Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period published in the CNS Drugs
    • 28 Feb 2023 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top